A Phase I Study of MRG-106 in Patients with Various Recurrent or Persistent Lymphomas and Leukemias


Full Title

MRG106-11-101: A Phase 1 Dose-Ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects with Various Lymphomas and Leukemias [RESTARTED FROM MED17-170]


The purpose of this study is to assess the safety of an investigational anticancer drug called MRG-106 in patients with different types of lymphomas and leukemias that have come back or continued to grow despite treatment. It belongs to a class of drugs called “oligonucleotide inhibitors” and works by inhibiting a protein involved in cancer cell growth called miR-155-5p.

Patients in this study will include those with mycosis fungoides cutaneous T-cell lymphoma (CTCL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), or adult T-cell lymphoma/leukemia (ATLL). They will receive the drug intravenously (by vein), subcutaneously (injection under the skin), or intratumorally (injected directly into a tumor).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have mycosis fungoides CTCL, DLBCL, CLL, or ATLL that has come back or continued to grow despite treatment.
  • Patients must recover from the serious side effects of prior therapies before entering the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Alison Moskowitz at 212-639-4839.